Abstract:Chronic inflammatory joint diseases (IJDs) affect 1% to 2% of the population in developed countries. IJDs include rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other forms of spondyloarthritis (SpA). Tobacco smoking is considered a significant environmental risk factor for developing IJDs. There are indications that smoking exacerbates the symptoms and worsens disease outcomes. The objective of this review was to investigate the evidence for effects of smoking cessation interventions on smoking cessation and disease activity in smokers with IJD. We searched the Cochrane Tobacco Addiction Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library; PubMed/MEDLINE; Embase; PsycINFO; the Cumulative Index to Nursing and Allied Health Literature (CINAHL); and three trials registers to October 2018. We included randomised controlled trials testing any form of smoking cessation intervention for adult daily smokers with a diagnosis of IJD, and measuring smoking cessation at least six months after baseline. We used standard methodological procedures as expected by Cochrane. We included two studies with 57 smokers with a diagnosis of rheumatoid arthritis (RA). We identified no studies including other IJDs. One pilot study compared a smoking cessation intervention specifically for people with RA with a less intensive, generic smoking cessation intervention. People included in the study had a mean age of 56.5 years and a disease duration of 7.7 years (mean). The second study tested effects of an eight‐week cognitive‐behavioural patient education intervention on cardiovascular disease (CVD) risk for people with RA and compared this with information on CVD risk only. The intervention encouraged participants to address multiple behaviours impacting CVD risk, including smoking cessation, but did not target smoking cessation alone. People included in the study had a mean age of 62.2 years (intervention group) and 60.8 years (control group), and disease duration of 11.6 years (intervention group) and 14.1 years (control group). It was not appropriate to perform a meta‐analysis of abstinence data from the two studies due to clinical heterogeneity between interventions. Neither of the studies individually provided evidence to show benefit of the interventions tested. Only one study reported on adverse effects. These effects were non‐serious, and numbers were comparable between trial arms. Neither of the studies assessed or reported disease activity or any of the predefined secondary outcomes. We assessed the overall certainty of evidence as very low due to indirectness, imprecision, and high risk of detection bias based on GRADE. We found very little research investigating the efficacy of smoking cessation intervention specifically in people with IJD. Included studies are limited by imprecision, risk of bias, and indirectness. Neither of the included studies investigated whether smoking cessation intervention reduced disease activity among people with IJD. High‐quality, adequately powered studies are warranted. In particular, researchers should ensure that they measure disease markers and quality of life, in addition to long‐term smoking cessation. Are smoking cessation interventions effective for quitting smoking and reducing disease activity in people with chronic inflammatory joint disease? Background Tobacco smoking increases the risk of developing inflammatory joint diseases (IJDs) such as rheumatoid arthritis, where the joints are progressively damaged by the body's own immune system. Smoking may also worsen symptoms of these diseases. This review looked at whether supportive programmes to help smokers with IJDs quit smoking actually lead to quitting and reduced inflammation in the joints and elsewhere. Inflammation from these diseases can lead to heart attack and stroke, for which people with IJD are at higher risk. Study characteristics We searched the literature in October 2018. We included two studies with a total of 57 adult smokers ‐ both men and women ‐ with rheumatoid arthritis. One of the studies tested an intervention to help people with rheumatoid arthritis to quit smoking. This study recruited only smokers and compared this specialist, stop smoking programme with a standard, less intensive stop smoking programme. The other study tested an intervention to reduce the risk of heart disease and stroke in people with rheumatoid arthritis. Researchers recruited non‐smokers and smokers and compared this programme to a brief factual information leaflet about risks of heart disease. Both studies followed study participants for six months. These studies were funded by Arthritis Research UK Educational Research Fellowship, Arthritis Research UK, the New Zealand Health Research Council, Arthritis New Zealand, and the University of Otago Research Fund. -Abstract Truncated-

Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database

Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients

Rheumatoid arthritis and changes on spirometry by smoking status in two prospective longitudinal cohorts

Impact of Cigarette Smoking on Rheumatoid Arthritis-Associated Lung Diseases: a Retrospective Case Control Study on Clinical and Radiological Features and Prognosis.

Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis

Current Cigarette Use in Rheumatoid Arthritis Patients: Associated Factors and a Limited Mediating Role of Depression

Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis

Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.

Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus

Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study

The impact of nicotine smoking on spondyloarthritis and rheumatoid arthritis

Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses’ Health Studies

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study

Active smoking effect in allergic rhinitis

Impact of sex, serostatus, and smoking on risk for rheumatoid arthritis‐associated interstitial lung disease subtypes

A Dense Mapping Of Hla Region For Study Of Interaction With Smoking In The Development Of Rheumatoid Arthritis

Do the Activity Indices Used in Axial Spondyloarthritis Capture the Relationships Between Obesity, Smoking and Disease Activity in the Same Way?

ARYL HYDROCARBON RECEPTOR MEDIATES SMOKING-INDUCED RHEUMATOID ARTHRITIS EXACERBATION

Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study

Association between secondhand smoke exposure and rheumatoid arthritis in US never-smoking adults: a cross-sectional study from NHANES